Table of Contents

State/Territory Name: Delaware

State Plan Amendment (SPA) #: 21-0005

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form (with 179-like data)
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services 601 E. 12th St., Room 355 Kansas City, Missouri 64106



Medicaid and CHIP Operations Group

November 3, 2021

Stephen Groff
Director
Division of Medicaid Medical Assistance
P.O. Box 906
New Castle, DE, 19720

Re: Delaware State Plan Amendment (SPA) 21-0005

Dear Mr. Groff:

The Centers for Medicare & Medicaid Services (CMS) reviewed your Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) DE-21-0005. This amendment proposes to add medication-assisted treatment (MAT) as a mandatory benefit in the Medicaid state plan. This letter is to inform you that Delaware's Medicaid SPA Transmittal Number DE-21-0005 was approved on November 3, 2021, effective October 1, 2020 until September 30, 2025, pursuant to 1905(a)(29) of the Social Security Act and Section 1006(b) of the SUPPORT Act.

Section 1006(b) of the SUPPORT for Patients and Communities Act (SUPPORT Act), signed into law on October 24, 2018, amended section 1902(a)(10)(A) of the Act to require state Medicaid plans to include coverage of MAT for all eligible to enroll in the state plan or waiver of state plan. Section 1006(b) also added a new paragraph 1905(a)(29) to the Act to include the new required benefit in the definition of "medical assistance" and to specify that the new required benefit will be in effect for the period beginning October 1, 2020, and ending September 30, 2025.

Section 1006(b) of the SUPPORT Act also added section 1905(ee)(1) to the Act to define MAT, for purposes of the new required coverage, as:

...all drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), including methadone, and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262) to treat opioid use disorders; and[,] ... with respect to the provision of such drugs and biological products, counseling services and behavioral therapy.

Pursuant to section 1135(b)(5) and 1135(b)(1)(C) of the Act, due to the COVID-19 public health emergency (PHE), CMS issued an approval letter on March 15, 2021 allowing Delaware to modify the SPA submission requirements at 42 C.F.R. 430.20, to allow the state to submit a SPA implementing section 1905(a)(29) of the Act by March 31, 2021 that would take effect on October 1, 2020.

CMS conducted our review of your submittal according to statutory requirements in Title XIX of the Act and implementing regulations.

If you have any questions, please contact Talbatha Myatt at 215-861-4259 or via email at Talbatha.Myatt@cms.hhs.gov.

Sincerely,

James G. Scott, Director Division of Program Operations

cc: Nicole Cunningham, State Plan Coordinator Kimberly Xavier, Chief, Policy & Planning

CENTERS FOR WEDICARE & WEDICAID SERVICES	I. ==	lo otate		
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	1. TRANSMITTAL NUMBER 2 1 0 0 5	2. STATE Delaware		
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID)			
TO: REGIONAL ADMINISTRATOR	4. PROPOSED EFFECTIVE DATE			
CENTERS FOR MEDICARE & MEDICAID SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	October 1, 2021 October 1, 2020			
5. TYPE OF PLAN MATERIAL (Check One)				
NEW STATE PLAN AMENDMENT TO BE CONSIDE		AMENDMENT		
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AMEND	MENT (Separate transmittal for each am	endment)		
6. FEDERAL STATUTE/REGULATION CITATION				
Title XIX Medicaid State Plan	a. FFY 2021 \$ 0 b. FFY 2122 \$ 0			
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	9. PAGE NUMBER OF THE SUPERSEL OR ATTACHMENT (If Applicable)	DED PLAN SECTION		
Attachment 3.I-A Page 2A, Attachment 4-19-B Page 18	Attachment 3.I-A Page 2A, Attachment	: 4-19-B Page 18		
10. SUBJECT OF AMENDMENT				
MAT				
11. GOVERNOR'S REVIEW (Check One)	_			
GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	✓ OTHER, AS SPECIFIED:			
12 SIGNATURE OF STATE AGENCY OFFICIAL 16.	. RETURN TO			
13. TYPED NAME Stephen M. Groff				
14. TITLE Director	Stephen M. Groff, Director, DMMA, P.O. Box 906 New Castle, DE19720			
15. DATE SUBMITTED				
FOR REGIONAL OFFICE USE ONLY				
17. DATE RECEIVED 18. 03/30/2021	. DATE APPROVED 11/03/2021			
PLAN APPROVED - ONE	COPY ATTACHED			
19. EFFECTIVE DATE OF APPROVED MATERIAL 20. 10/01/2020	. SIGNATURE OF REGIONAL OFFICIAL			
21. TYPED NAME 22.	TITLE			
James G. Scott	Director Program Operations			
23. REMARKS Division of Program Operations				
10/15/2021- Delaware requested CMS to make a pen & ink change to box	x #4 to reflect 10/1/2020 as the proposed	effective date.		

Enclosure

Supplement to Attachment 3.1-A

Page 2A

State of Delaware

1905(a)(29) Medication-Assisted Treatment (MAT)

Citation: 3.1(a)(1) Amount, Duration, and Scope of Services: Categorically Needy

(Continued)

1905(a)(29) X MAT as described and limited in Supplement to Attachment 3.1-A Page 2A.

ATTACHMENT 3.1-A identifies the medical and remedial services provided to

the categorically needy.

TN No. SPA 21-0005

Supersedes

TN No. SPA 13-018 Effective Date October 1, 2020

Page 2B

State of Delaware

1905(a)(29) Medication-Assisted Treatment (MAT)

Amount, Duration, and Scope of Medical and Remedial Care Services Provided to the Categorically Needy (continued)

i. General Assurance

MAT is covered under the Medicaid state plan for all Medicaid beneficiaries who meet the medical necessity criteria for receipt of the service for the period beginning October 1, 2020, and ending September 30, 2025.

ii. Assurances

- a. The state assures coverage of Naltrexone, Buprenorphine, and Methadone and all of the forms of these drugs for MAT that are approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262).
- b. The state assures that Methadone for MAT is provided by Opioid Treatment Programs that meet the requirements in 42 C.F.R. Part 8.
 - The state assures coverage of all current and future formulations of drugs prescribed or administered for MAT that are approved for the treatment of OUD under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all current and future formulations of biological.

iii. Service Package

The state covers the following counseling services and behavioral health therapies as part of MAT.

- a) Please set forth each service and components of each service (if applicable), along with a description of each service and component service.
 - 1) Assessment and clinical treatment plan development The purpose of the assessment is to provide sufficient information for problem identification.
 - 2) Skill development for coping with and managing symptoms and behaviors associated with opioid use disorders (OUD) such as the participant

TN No. SPA <u>21-0005</u>	Approval Date <u>11/03/2021</u>
Supersedes	
TN No. SPA <u>13-018</u>	Effective Date October 1, 2020

State of Delaware

1905(a)(29) Medication-Assisted Treatment (MAT)

Amount, Duration, and Scope of Medical and Remedial Care Services Provided to the Categorically Needy (continued)

perspective and lack of impulse control or signs and symptoms of withdrawal.

- 3) Counseling to address a beneficiary's major lifestyle, attitudinal, and behavioral problems. Counseling includes highly structured psychosocial therapy to address issues that have the potential to undermine the goals of treatment.
- b) Please include each practitioner and provider entity that furnishes each service and component service.

All providers listed below may provide any service and its related components with the exception that recovery coaches cannot perform assessments.

- Licensed Clinical Social Workers (LCSWs)
- Licensed Professional Counselors of Mental Health (LPCMH)
- Licensed Marriage and Family Therapists (LMFTs), nurse practitioners (NPs)
- Advanced practice nurses (APNs)
- Medical doctors (MD and DO)
- Licensed Chemical Dependency Professionals (LCDPs)
- Psychologists
- Certified Recovery Coach
- Credentialed Behavioral Health Technician
- Registered Nurses
- Licensed Practical Nurses
- Certified alcohol and drug counselor (CADC)
- Internationally certified alcohol and drug counselor (ICADC)
- Certified co-occurring disorders professional (CCDP)
- Internationally certified co-occurring disorders professional (ICCDP)
- Internationally certified co-occurring disorders professional diplomate (ICCDP-D)

TN No. SPA <u>21-0005</u>	Approval Date <u>11/03/2021</u>
Supersedes	
TN No. SPA <u>13-018</u>	Effective Date October 1, 2020

Enclosure

Page 2D

State of Delaware

1905(a)(29) Medication-Assisted Treatment (MAT)

Amount, Duration, and Scope of Medical and Remedial Care Services Provided to the Categorically Needy (continued)

- c) Please include a brief summary of the qualifications for each practitioner or provider entity that the state requires. Include any licensure, certification, registration, education, experience, training and supervisory arrangements that the state requires.
 - Certified Recovery Coach Credentialed by DHSS or its designee. State regulations require supervision by QHP meeting the supervisory standards established by DHSS or its designee. A QHP includes the following professionals who are currently registered with their respective Delaware board LCSWs, LPCMHs, and LMFTs, APNs, NPs, CADCS, LCDPs, medical doctors (MD and DO), and psychologists. Clinical Supervisors includes individuals who have a Bachelor's degree in chemical dependency, psychology, social work counseling, nursing or a related field and have either: 1) Five (5) years of related clinical experience or 2) full certification as a CADCs, ICADCs, CCDPs, ICCDPs, and ICCDP-Ds. All Clinical Supervisors must meet these requirements by January 1, 2018. The QHP or Clinical Supervisor provides clinical/administrative oversight and supervision of Certified Recovery Coaches and Credentialed Behavioral Health Technicians staff in a manner consistent with their scope of practice.
 - Credentialed Behavioral Health Technician Credentialed by DHSS or its designee. State regulations require supervision by OHP meeting the supervisory standards established by DHSS or its designee. A QHP includes the following professionals who are currently registered with their respective Delaware board LCSWs, LPCMHs, and LMFTs, APNs, NPs, CADCS, LCDPs, medical doctors (MD and DO), and psychologists. Clinical Supervisors includes individuals who have a Bachelor's degree in chemical dependency, psychology, social work counseling, nursing or a related field and have either: 1) Five (5) years of related clinical experience or 2) full certification as a CADCs, ICADCs, CCDPs, ICCDPs, and ICCDP-Ds. All Clinical Supervisors must meet these requirements by January 1, 2018. The QHP or Clinical Supervisor provides clinical/administrative oversight and supervision of Certified Recovery

TN No. SPA 21-0005 Supersedes TN No. SPA 13-018

Approval Date 11/03/2021

Effective Date October 1, 2020

Encl	losure	

Page 2E

State of Delaware

1905(a)(29) Medication-Assisted Treatment (MAT)

Amount, Duration, and Scope of Medical and Remedial Care Services Provided to the Categorically Needy (continued)

Coaches and Credentialed Behavioral Health Technicians staff in a manner consistent with their scope of practice.

- Certified alcohol and drug counselor (CADC) Certified and Credentialed under Delaware state regulation.
- Internationally certified alcohol and drug counselor (ICADC) Certified and Credentialed under Delaware state regulation.
- Certified co-occurring disorders professional (CCDP) Certified and Credentialed under Delaware state regulation.
- Internationally certified co-occurring disorders professional (ICCDP) Certified and Credentialed under Delaware state regulation.
- Internationally certified co-occurring disorders professional diplomate (ICCDP-D) Certified and Credentialed under Delaware state regulation.

TN No. SPA <u>21-0005</u> Supersedes

TN No. SPA 13-018

Approval Date 11/03/2021

Effective Date October 1, 2020

Enclosure
Supplement to Attachment 3.1-A
Page 2F
State of Delaware
1905(a)(29) Medication-Assisted Treatment (MAT)
Amount, Duration, and Scope of Medical and Remedial Care Services Provided to the Categorically Needy (continued)
iv. Utilization Controls
X_ The state has drug utilization controls in place. (Check each of the

__X_ Generic first policy _X__ Preferred drug lists X Clinical criteria X Quantity limits

The state does not have drug utilization controls in place.

Limitations v.

following that apply)

Describe the state's limitations on amount, duration, and scope of MAT drugs, biologicals, and counseling and behavioral therapies related to MAT.

TN No. SPA 21-0005 Approval Date 11/03/2021 Supersedes TN No. SPA 13-018 Effective Date October 1, 2020

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT STATE/TERRITORY: **DELAWARE**METHODS AND STANDARDS FOR ESTABLISHING PAYMENT RATES — OTHER TYPES OF CARE

Payments for Medication Assisted Treatment

Effective October 1, 2020, the Medicaid agency will continue to pay qualified providers for evaluation and management (E/M) or HCPCS Code as applicable when Medication Assisted Treatment (MAT) is part of a visit.

Delaware will pay Psychologists at 100% of the Medicare physician rates. If a Medicare fee exists for a defined covered procedure code, then Delaware Medicaid will pay other Licensed professionals listed in Attachment 3.1-A Page 6r and Attachment 3.1-A Page 6s at 75% of the Medicaid physician rates as outlined under Attachment: 4.19-B, item 5.

Unbundled prescribed drugs for MAT shall be reimbursed using the same methodology as described in Attachment 4.19-B for covered outpatient drug reimbursement and in the table on Attachment 4.19-B Page 14a for prescribed drugs that are dispensed or administered.

TN No. SPA <u>21-0005</u>

Supersedes

TN No. SPA 13-018

Approval Date 11/03/2021

Effective Date October 1, 2020